Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Scientists develop vaccine for fusobacterium necrophorum
Fusobacterium necrophorum causes infection in livestock and people, but scientists at Kansas State University have found a way to protect animals and humans from the virus.

Bacterium affects both livestock and people

A vaccine that could provide effective, antibiotic-free prevention of Fusobacterium infection has been developed by scientists at Kansas State University.

Fusobacterium necrophroum infection affects both livestock and people. Currently, antibiotics are used to control the bacterium, but researchers say the new vaccine takes an altogether different approach.

"The Food and Drug Administration has prevented the use of many antibiotics in cattle, especially those similar to ones with human applications, so this vaccine is an alternative,” commented Sanjeev K. Narayanan, professor of diagnostic medicine and pathobiology. 

“This way, we don't expose people's food to as many antibiotics, so the vaccine protects both animals and humans."

The vaccine uses a two-pronged approach. It first immunises the animal against leukotoxins, which kill white blood cells and Kupffer cells - the liver’s natural weapons against bacteria.

The team found that Fusobacterium bacterium is able to survive in the liver because it produces leukotoxins. By immunising, if the bacterium enters the liver, there are antibodies built up against it, and the antibodies will neutralise the toxin.

The second element of the vaccine was developed in the lab, where the team identified the protein that allows the bacterium to attach to the walls of the rumen and the liver.

They were then able to identify a major protein in Fusobacterium necrophorum that is responsible for attaching to organs. Antibodies generated in the animal against the protein will prevent bacterial attachment.

"If you can prevent attachment, you can prevent infection," said T.G Nagaraja, a distinguished professor of microbiology. "That's why this patented vaccine uses a two-pronged approach."

The team says the vaccine is currently in testing for cattle, and may eventually be available also for sheep and for people.

Image (C) Kansas State University

Become a member or log in to add this story to your CPD history

Submissions open for BSAVA Clinical Research Abstracts 2026

News Story 1
 The BSAVA has opened submissions for the BSAVA Clinical Research Abstracts 2026.

It is an opportunity for applicants to present new research on any veterinary subject, such as the preliminary results of a study, discussion of a new technique or a description of an interesting case.

They must be based on high-quality clinical research conducted in industry, practice or academia, and summarised in 250 words.

Applications are welcome from vets, vet nurses, practice managers, and students.

Submissions are open until 6 March 2026. 

Click here for more...
News Shorts
Survey seeks ruminant sector views on antimicrobial stewardship

A new survey is seeking views of people working in the UK ruminant sector on how to tackle the challenge of demonstrating responsible antibiotic stewardship.

Forming part of a wider, collaborative initiative, the results will help identify the types of data available so that challenges with data collection can be better understood and addressed.

Anyone working in the UK farming sector, including vets and farmers,is encouraged to complete the survey, which is available at app.onlinesurveys.jisc.ac.uk